Once-Weekly Insulin Better Than Daily in Type 2 Diabetes

<?xml version="1.0" encoding="UTF-8"?>
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>166769</fileName> <TBEID>0C04E550.SIG</TBEID> <TBUniqueIdentifier>MD_0C04E550</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240131T110451</QCDate> <firstPublished>20240131T110819</firstPublished> <LastPublished>20240131T110819</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240131T110819</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>Drishti Agarwal</byline> <bylineText>DRISHTI AGARWAL</bylineText> <bylineFull>DRISHTI AGARWAL</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>Once-weekly insulin icodec shows a higher glycated A1c reduction than once-daily basal insulin analogs in patients with type 2 diabetes (T2D), without major saf</metaDescription> <articlePDF/> <teaserImage/> <teaser>Weekly insulin icodec better at reducing A1c daily basal insulin analogs glargine and degludec over 26-78 months.</teaser> <title>Once-Weekly Insulin Better Than Daily in Type 2 Diabetes</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>dbh</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> <journalTitle/> <journalFullTitle/> <copyrightStatement/> </publicationData> <publicationData> <publicationCode>icymit2d</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>endo</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term>15</term> <term>21</term> <term>358</term> <term>71871</term> <term canonical="true">34</term> </publications> <sections> <term canonical="true">27970</term> <term>39313</term> <term>65288</term> </sections> <topics> <term canonical="true">205</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Once-Weekly Insulin Better Than Daily in Type 2 Diabetes</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p>Once-weekly insulin icodec shows a higher glycated <span class="Hyperlink">A1c</span> reduction than once-daily basal insulin analogs in patients with <span class="Hyperlink">type 2 diabetes</span> (T2D), without major safety concerns.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>A meta-analysis of five phase 3 ONWARDS randomized controlled trials included 3764 patients with T2D.</li> <li>The trials compared the effects of the weekly insulin icodec with those of the daily basal insulin analogs glargine and degludec over 26-78 months.</li> <li>The primary outcome was the change in A1c levels.</li> <li>Secondary outcomes included fasting plasma glucose levels, A1c levels &lt; 7%, time in target glycemic range, body weight changes, insulin dose, <span class="Hyperlink">hypoglycemia</span> events, and adverse events.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li/> <li>A1c levels &lt; 7% were observed in a higher percentage of patients in the insulin icodec group than in the comparator group (odds ratio, 1.51; <em>P</em> = .004).</li> <li>In subgroup analyses, insulin icodec was superior to <span class="Hyperlink">insulin degludec</span> by several measures but comparatively similar to glargine.</li> <li>Insulin icodec was associated with no major safety concerns and had a slightly higher incidence of levels 1, 2, and combined 2/3 than degludec but no significant differences compared with glargine.</li> </ul> <h2>IN PRACTICE:</h2> <p>“Sustained glycemic control with once-weekly injections of insulin icodec would lead to better patient acceptance and treatment satisfaction,” the authors wrote.</p> <h2>SOURCE:</h2> <p>This study, authored by Sahana Shetty, MD, and Renuka Suvarna, MSc, Manipal Academy of Higher Education, Department of Endocrinology, Kasturba Medical College, Manipal, Karnataka, was <span class="Hyperlink"><a href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15408">published online</a></span> on January 8, 2024, in <em>Diabetes, Obesity and Metabolism</em>.</p> <h2>LIMITATIONS:</h2> <p>The comparator group included individuals who used different basal insulin analogs. This heterogeneity in the comparator group introduced a potential source of variability, making it challenging to isolate the specific effects of insulin icodec compared with a standardized comparator. Blinding or masking of participants was performed in only one of the five trials.</p> <h2>DISCLOSURES:</h2> <p>The authors declared no conflicts of interest. All five clinical trials in the meta-analysis were sponsored by Novo Nordisk.<br/><br/></p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/once-weekly-insulin-better-than-daily-type-2-diabetes-2024a100024c">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>